stockrow
Saturday 7 November 2026
Export KTTA’s income statement to Excel — free account
Pasithea Therapeutics Corp.
KTTA Healthcare Biotechnology
- EPS
- +75.8%
- Free cash flow
- −21.7%
Quarter to June 2026, against a year earlier
0.58
0.06
+11.54%
Follow KTTA
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Jun ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | 0 | — | — | — | — | 0 | — | — | — | — | — | |
| Gross margin, % | — | — | — | — | — | (14.57) | 76.74 | — | — | — | 0.00 | +91.3 pt | ||||||
| EBT | — | — | — | — | 0 | (2) | (12) | (16) | (14) | (20) | (21) | +246.3% | ||||||
| EBT margin, % | — | — | — | — | 0.00 | (14,394.04) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| Net income | — | 0 | — | — | 0 | (2) | (12) | (16) | (14) | (20) | (21) | n/m | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | — | — | — | — | 0.00 | 0.03 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | n/m | |||||
| Earnings | — | — | — | — | (0.11) | (4.18) | (10.91) | (13.01) | (12.69) | (2.91) | (1.48) | +92.1% | ||||||
| Cash flow | — | — | — | — | (0.11) | (6.10) | (9.43) | (10.44) | (12.70) | (2.16) | (0.55) | +83.1% | ||||||
| Capex | — | — | — | — | 0.00 | (0.04) | (0.08) | 0.06 | 0.00 | 0.00 | 0.00 | n/m | ||||||
| Free cash flow | — | — | — | — | (0.11) | (6.14) | (9.51) | (10.38) | (12.70) | (2.16) | (0.55) | +83.1% | ||||||
| Book value | — | — | — | — | 0.66 | 98.83 | 33.68 | 19.07 | 13.49 | 7.85 | 1.55 | +64.3% | ||||||
| Shares, m | — | — | — | — | 0 | 1 | 1 | 1 | 1 | 7 | 19 | +80.4% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | 0.00 | 0.00 | — | — | — | 0.00 | 0.0 | |||||
| P/S | — | — | — | — | — | 0.00 | 33.35 | — | — | — | 38.26 | 16.7 | ||||||
| P/B | — | — | — | — | — | 0.36 | 0.38 | — | — | — | 0.37 | 0.4 | ||||||
| EV/Sales | — | — | — | — | — | 0.00 | (34.65) | — | — | — | (55.79) | (17.3) | ||||||
| EV/FCF | — | — | — | — | — | 10.81 | 1.40 | — | — | — | 1.54 | 6.1 | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | 0 | (3) | (12) | (13) | (14) | (15) | (18) | +230.3% | |||||
| Capex | — | — | — | — | — | 0 | 0 | 0 | — | 0 | 0 | n/m | ||||||
| Free cash flow | — | — | — | — | 0 | (3) | (12) | (13) | (14) | (15) | (18) | +230.2% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | — | — | — | — | 0 | 53 | 32 | 14 | 6 | 51 | 46 | +192.3% | |||||
| Net debt | — | — | — | — | 0 | (53) | (33) | (16) | (7) | (55) | (46) | +195.9% | ||||||
| Shareholders’ equity | — | — | — | — | 0 | 51 | 42 | 23 | 15 | 55 | 50 | +196.4% | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | — | — | — | — | (33.06) | (8.11) | (28.30) | (44.78) | (65.93) | (53.54) | (61.97) | (20.5) pt | |||||
| ROIC | — | — | — | — | 0.00 | 0.00 | (83.61) | (141.31) | (113.31) | 0.00 | (367.46) | 0.0 pt | ||||||
| ROE | — | — | — | — | (0.16) | (8.41) | (29.68) | (48.44) | (72.83) | (58.36) | (65.49) | (58.2) pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | — | — | — | 3 | 5 | 15 | 8 | 4 | 5 | — | +10.8% | |||||
| Revenue/emp, $m | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | n/m | ||||||
Negative figures in brackets.
estimates
Fiscal years to Dec 2021 · latest quarter Jan 0001 · fundamentals updated 26 Oct 2026
Pasithea Therapeutics Corp. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| COCP Cocrystal Pharma, Inc. | $19.3M | — (loss-making) | — (loss-making) | −81.05% (below 0%: shrinking) | n/m | −16.75% (below 0%: shrinking) | 100.00% | (3,032.38%) | Compare |
| QNRX Quoin Pharmaceuticals, Ltd. Sponsored ADR | $18.5M | — (loss-making) | — | — | n/m | −510.28% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| ACTU Actuate Therapeutics, Inc. | $18.0M | — (loss-making) | — | — | n/m | −5.54% (below 0%: shrinking) | — | 0.00% | Compare |
| ESLA Estrella Immunopharma, Inc. | $17.8M | — (loss-making) | — | — | n/m | −329.19% (below 0%: shrinking) | — | 0.00% | Compare |
| KTTA Pasithea Therapeutics Corp. | $17.4M | — (loss-making) | — (loss-making) | +1,494.04% (above 0%: growing) | n/m | −21.68% (below 0%: shrinking) | 0.00% | 0.00% | |
| CNTX Context Therapeutics Inc. | $17.3M | — (loss-making) | — | — | n/m | −20.61% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| QNTM Quantum Biopharma Ltd. | $17.1M | — (loss-making) | — (loss-making) | — | n/m | +5.88% (above 0%: growing) | 0.00% | 0.00% | Compare |
| JSPR Jasper Therapeutics, Inc. | $15.6M | — (loss-making) | — | — | n/m | +55.74% (above 0%: growing) | 0.00% | 0.00% | Compare |
| NCEL NewcelX Ltd. | $15.6M | — (loss-making) | — | — | n/m | −87.71% (below 0%: shrinking) | 0.00% | — | Compare |
| Median of peers | $17.6M | — | — | — | — | −18.68% | 0.00% | 0.00% |
Pay and ownership Proxy statement filed 7 August 2026
Ownership
Directors and executive officers, together
1.50%
Janus Henderson Group plc
9.99%
Vivo Opportunity Fund Holdings, L.P.
9.99%
Coastlands Capital LP
7.00%
Adage Capital Management, L.P.
6.90%
Squadron Capital Management, LLC
6.90%
Opaleye Management Inc.
6.10%
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more.
Read the proxy statement